AIM ImmunoTech reports positive Phase III data of Ampligen for long Covid

AIM ImmunoTech has reported positive initial pilot study data from its Phase III trial of an investigational drug, Ampligen, for long Covid.

Related Keywords

Thomas Equels ,Electronic Data Capture Solutions For Clinical Trials ,Contract Manufacturing Organisation ,Contract Research Organisation For Clinical Trials ,Drug Administration ,Access Program ,Expanded Access Program ,Research Organisation ,Manufacturing Organisation ,Pharmaceutical Supply ,Data Capture Solutions ,